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30–35ml/min as stated in the present KDIGO clinical practice
guidelines may be too low.
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The Authors Reply: For patients with chronic kidney disease
stage 3 without evidence of bone or mineral disorder,
the Kidney Disease Improving Global Outcomes workgroup
recommended treatment for osteoporosis as in the general
population. Over 80% of women with osteoporosis have
chronic kidney disease stage 3 or 4 (ref. 1). Most of these
elderly patients with age-related chronic kidney disease are
not examined by nephrologists. In determining appropriate
therapy for osteoporosis, the reduction in hip fracture and,
potentially, in mortality, must be balanced against adverse
events. In the pivotal trials of zoledronic acid, a transient
increase in serum creatinine was noted in 1.3% of the
patients on the drug and in 0.4% on placebo in 3889
osteoporotic patients.2 In a study of 1065 patients with a
recent hip fracture, an increase in serum creatinine was seen
in 6.2% of patients on the drug and 5.6% on placebo. There
was a 28% reduction in overall mortality with the drug.3
As Dr Woo has written, there are some newer reports
of renal damage that have emerged from post-marketing
surveillance.4 However, the incidence of these adverse events
is still low, 18 per 100,000 per year, and most of the patients
had only a transient increase in creatinine. Thus, preventing
the devastating consequences of a hip fracture will usually
outweigh this small risk of kidney damage. To reduce the risk,
physicians should follow guidelines about infusion rates,
avoid volume depletion, or the administration of concomitant
nephrotoxic medications. In addition, using oral dosing may
help reduce this risk.
Once the kidney disease has progressed to chronic kidney
disease–mineral and bone disorder (which is not determined
by the estimated glomerular ﬁltration rate but by abnormal-
ities in calcium, phosphate, parathyroid hormone, or alkaline
phosphatase), there is very little evidence about either safety
or efﬁcacy because these patients were excluded from
the clinical trials. Therefore, we could not recommend the
use of these drugs in the Kidney Disease Improving Global
Outcomes guidelines. These patients must be treated on
an individual basis, and we agree that the possibility of
aggravated progression of renal disease should now be taken
into consideration.
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Hypophosphatemia in patients
with autosomal dominant
polycystic kidney disease: the role
of fibroblast growth factor 23 or
loss of sodium/phosphate
cotransporter?
To the Editor: We read with great interest the contribution
by Pavik et al.1 They reported increased ﬁbroblast growth
factor 23 (FGF23) and decreased serum phosphate levels in
autosomal dominant polycystic kidney disease (ADPKD), and
speculated the association between FGF23 and increased
renal phosphate excretion. We would like to suggest another
possible mechanism of hypophosphatemia in ADPKD
patients.
According to an in vivo study by Vogel et al.,2 the type II
sodium/phosphate cotransporter (NaPi-2) in the brush
border membrane (BBM) of proximal tubules has the central
role of renal phosphate (Pi) absorption. During progression
of ADPKD, the proximal nephron is damaged by the
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